Overall verdict
Neutral
4.7/10
1-year performance
+56.07%
Score breakdown
Up 56.1% over 1 year, 55% of the 52-week range.
Strongest: Growth 9.5/10. Weakest: Profitability 0.0/10.
22 analysts, target +0.3% vs the price.
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer ; Latitude, a blood-based MRD test for colorectal cancer ; Altera, a tissue based comprehensive genomic profiling test ;
and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses ;
Empower, a hereditary cancer screening test ; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation ; Renasight, a kidney gene panel test ; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services.
The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Solomon Moshkevich
Founded
2003
Employees
6 140
Revenue / employee
375 588 USD
Next earnings
February 26, 2027 (estimated)
Institutional holders
- FMR LLC9.43%
- GEODE CAPITAL MANAGEMENT, LLC1.86%
- Bank of New York Mellon Corp0.37%
- Rest of the register88.33%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
437.41 USD
52-week low
181.00 USD
1-year performance
56.07%
Rising
Year-to-date performance
40.92%
Rising
Drawdown
-26.24%
Marked drawdown
Position in the 52-week range
55% of range
Against the world ETF
Over 11 years, from July 2015 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned much more, but shaking 4.6 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of July 2015 are worth today
| Natera | $229,022 |
| World ETF | $33,627 |
| S&P 500 | $43,168 |
| Risk-free placement | $12,824 |
The risk
- Shaking:the share moves 4.6 times as much as the world ETF.
- Worst fall:-78 % between September 2021 and May 2022. $10,000 placed at the top fell to $2,226. The world ETF, at worst: -34 %. Back to its high in 28 months.
Natera earned 7 times as much as the world ETF since 2015
Value of $10,000 placed at the end of July 2015, dividends reinvested, in dollars
- Natera: $229,022
- World ETF: $33,627
- S&P 500: $43,168
- Risk-free placement: $12,824
Based on past performance. This is not a recommendation.
Gross margin 64.5%, the company loses 5.7% of its revenue, ROIC -9.8%, ROE -10.6%.
Net margin
-5.66%
Negative
Sector -14.06%|S&P 13.40%
Gross margin
64.50%
Fair
Return on equity (ROE)
-10.55%
Negative
Sector -18.81%|S&P 17.06%
Return on invested capital (ROIC)
-9.78%
Negative
Free cash flow margin (FCF)
1.80%
Low
Margin stability
21.2 pts
Very uneven
Revenue to net income
Growth
9.5/10Revenue up 34.1% over 1 year, 42.6% a year over 5.
Revenue (trailing 12 months)
2.9Md USD
Revenue growth (1y)
34.08%
Hyper-growth
Revenue growth (3y)
181.16%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 31.0x|S&P 23.6x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 17.4x|S&P 15.5x
PEG
—
Sector -0.08|S&P 0.91
Market cap
46.8Md USD
Financial strength
7.2/10Cash covers 459.4% of the debt, net debt/EBITDA 0.9x.
Net debt / EBITDA
0.9x
Solid
Gearing (net debt / equity)
-45.91%
Net cash
Cash
1.1Md USD
Cash / market cap
2.35%
Stretched
Cash / total debt
459.38%
Net cash
Interest coverage
-70.8x
Stretched
Net debt
-858M USD
Equity
1.9Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 311.98 USD
- MM20388.63
- MM50379.93
- MM200270.09
- RSI 1430.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+6.25%
200-day average slope, 3 months
+20.06%
50-day average slope, 1 month
+9.17%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
4.54 % per day
Volatility change
+41.76%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -1.54 (17) | -1.53 (15) | 3 006 (17) | -194 (11) | -223 (14) |
| 2027 | -0.39 (17) | -0.34 (15) | 3 645 (19) | -4 (11) | -46 (14) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 416 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 6.6 | 6.1 | 60.3Md USD | 38.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.8 % | 16.9 % | ||
| 2 | REGN | 6.4 | 6.1 | 99.2Md USD | 21.2x | 28.5 % | 36.3 % | 13.9 % | -1.3x | 3.9 % | 47.3 % | ||
| 3 | ABBV | 6.1 | 5.0 | 521Md USD | 50.8x | 15.6 % | 10.3 % | 16.1 % | 2.2x | 3.6 % | 34.7 % | ||
| 4 | VRTX | 5.6 | 4.1 | 139Md USD | 35.2x | 30.5 % | 10.4 % | 17.5 % | -0.9x | 2.3 % | 29.2 % | ||
| 5 | AMGN | 5.5 | 5.3 | 253Md USD | 27.2x | 24.1 % | 8.1 % | 14.7 % | 2.9x | 3.8 % | 44.7 % | ||
| 6 | NTRA | 4.7 | 3.0 | 46.8Md USD | Not meaningful (loss) | -5.7 % | 34.1 % | -9.8 % | 0.9x | 0.1 % | 56.1 % | ||
| 7 | CSL | 4.6 | 3.7 | 65.9Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | 14.8 % | ||
| 8 | GILD | 4.2 | 2.9 | 211Md USD | Not meaningful (loss) | -12.4 % | 6.7 % | -9.6 % | 1.1x | 6.5 % | 43.1 % | ||
| 9 | MRNA | 3.3 | 1.3 | 101Md USD | Not meaningful (loss) | -110.5 % | 29.2 % | -26.5 % | 0.4x | -2.0 % | 896.8 % |
